Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma
Alessandro Loglio(Ospedale Papa Giovanni XXIII), Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), G. Grossi(University of Milan), Paolo Corradini(Gruppo di Ricerca Geriatrica), Alessandra Pompa(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), G. Lunghi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Luca Baldini(University of Milan), Sara Labanca(University of Milan), F. Facchetti(University of Milan), Maria Grazia Rumi(University of Milan), Mauro Viganò(Ospedale San Giuseppe), Maria Goldaniga(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Lucia Farina(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 16
Related Papers
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
|Hepatology|2012|405
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|394
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346